HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Return
11.46%
This Quarter Return
+5.45%
1 Year Return
+11.46%
3 Year Return
+50.01%
5 Year Return
+144.68%
10 Year Return
–
AUM
$2.69B
AUM Growth
+$223M
(+9.1%)
Cap. Flow
+$99M
Cap. Flow
% of AUM
3.68%
Top 10 Holdings %
Top 10 Hldgs %
40.81%
Holding
106
New
52
Increased
14
Reduced
12
Closed
23
Top Buys
| 1 |
Danaher
DHR
|
$121M |
| 2 |
Incyte
INCY
|
$91.4M |
| 3 |
Encompass Health
EHC
|
$82.3M |
| 4 |
Cencora
COR
|
$68.9M |
| 5 |
Petco
WOOF
|
$68.4M |
Top Sells
| 1 |
Madrigal Pharmaceuticals
MDGL
|
$100M |
| 2 |
Cooper Companies
COO
|
$89.3M |
| 3 |
Bio-Rad Laboratories Class A
BIO
|
$81.7M |
| 4 |
Bristol-Myers Squibb
BMY
|
$80.5M |
| 5 |
Aurinia Pharmaceuticals
AUPH
|
$77.7M |
Sector Composition
| 1 | Healthcare | 88.14% |
| 2 | Real Estate | 4.75% |
| 3 | Consumer Discretionary | 2.55% |
| 4 | Financials | 1.64% |
| 5 | Technology | 1.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Align Technology
ALGN
$9.71B
| $38.7M | 1.37% |
+71,460
| New | +$38.7M |
|
27
CONMED
CNMD
$1.69B
| $36.2M | 1.28% |
276,940
+176,940
| +177% | +$23.1M |
|
28
Guardant Health
GH
$7.48B
| $33.5M | 1.18% |
219,300
-323,860
| -60% | -$49.4M |
|
29
Elevance Health
ELV
$69.6B
| $32.9M | 1.17% |
+91,760
| New | +$32.9M |
|
|
NUAN
30
DELISTED
Nuance Communications, Inc.
NUAN
| $32.4M | 1.15% |
+742,030
| New | +$32.4M |
|
31
Halozyme
HALO
$8.68B
| $31.1M | 1.1% |
+745,605
| New | +$31.1M |
|
32
Syndax Pharmaceuticals
SNDX
$1.37B
| $30.7M | 1.09% |
1,371,480
+300,930
| +28% | +$6.73M |
|
33
Royalty Pharma
RPRX
$15.8B
| $25.8M | 0.91% |
590,790
-748,740
| -56% | -$32.7M |
|
34
Ultragenyx Pharmaceutical
RARE
$3.02B
| $23.6M | 0.84% |
+207,610
| New | +$23.6M |
|
35
Acadia Pharmaceuticals
ACAD
$4.33B
| $23.2M | 0.82% |
+900,490
| New | +$23.2M |
|
36
Biogen
BIIB
$20.3B
| $22.5M | 0.8% |
80,510
+70,950
| +742% | +$19.8M |
|
37
Veeva Systems
VEEV
$44B
| $22.4M | 0.79% |
+85,900
| New | +$22.4M |
|
38
Sotera Health
SHC
$4.37B
| $20.1M | 0.71% |
+805,220
| New | +$20.1M |
|
|
LGV.U
39
DELISTED
Longview Acquisition Corp. II Units, each consisting of one share of Class A Common Stock and one-fifth of one redeemable Warrant
LGV.U
| $17.6M | 0.62% |
+1,750,000
| New | +$17.6M |
|
40
Allogene Therapeutics
ALLO
$240M
| $17.5M | 0.62% |
+494,640
| New | +$17.5M |
|
41
BioMarin Pharmaceuticals
BMRN
$10.9B
| $17.2M | 0.61% |
227,450
+5,240
| +2% | +$396K |
|
42
Haemonetics
HAE
$2.58B
| $16.5M | 0.58% |
148,480
-417,890
| -74% | -$46.4M |
|
43
Travere Therapeutics
TVTX
$1.82B
| $15.4M | 0.55% |
+618,520
| New | +$15.4M |
|
44
Arcus Biosciences
RCUS
$1.22B
| $15.1M | 0.53% |
+536,970
| New | +$15.1M |
|
45
eHealth
EHTH
$120M
| $13.1M | 0.46% |
+180,000
| New | +$13.1M |
|
|
AFMD
46
DELISTED
Affimed
AFMD
| $12.6M | 0.44% |
+158,794
| New | +$12.6M |
|
|
47
Aurinia Pharmaceuticals
AUPH
$1.63B
| $12.3M | 0.44% |
950,000
-5,987,448
| -86% | -$77.7M |
|
|
ARYD
48
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
| $12.1M | 0.43% |
+1,159,360
| New | +$12.1M |
|
49
Curis
CRIS
$21.4M
| $11.1M | 0.39% |
48,898
-69,821
| -59% | -$15.8M |
|
50
Cytokinetics
CYTK
$5.93B
| $10.8M | 0.38% |
+462,500
| New | +$10.8M |
|